| |
| |
|
| Insider
Information: |
Stahl Neil |
| Relationship: |
EVP Research and Devel... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
50,999 |
|
|
Indirect Shares
|
10,439 |
|
|
| Direct
Value |
$49,464,440 |
|
|
|
Indirect Value
|
$10,124,890 |
|
|
| Total
Shares |
61,438 |
|
|
| Total
Value |
$59,589,331 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 57.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regeneron Pharmaceuticals Inc |
REGN |
EVP Research and Devel... |
2024-02-26 |
50,999 |
2024-02-26 |
10,439 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2009-07-24 |
4 |
OE |
$9.49 |
$949,000 |
D/D |
100,000 |
89,813 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-11-05 |
4 |
OE |
$21.25 |
$2,828,500 |
D/D |
100,000 |
78,377 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res & Dev Sciences |
• – – |
2012-06-18 |
4 |
OE |
$20.32 |
$1,932,005 |
D/D |
95,079 |
154,200 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-08-04 |
4 |
OE |
$270.43 |
$25,690,850 |
D/D |
95,000 |
147,795 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2011-04-04 |
4 |
OE |
$13.00 |
$1,200,004 |
D/D |
92,308 |
142,658 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2011-09-06 |
4 |
OE |
$11.64 |
$964,002 |
D/D |
82,818 |
133,168 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-12-03 |
4 |
OE |
$179.13 |
$12,986,925 |
D/D |
72,500 |
101,309 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-08-04 |
4 |
D |
$613.00 |
$43,656,634 |
D/D |
(71,218) |
76,577 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-02-13 |
4 |
OE |
$8.50 |
$566,661 |
D/D |
66,666 |
92,177 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2009-07-24 |
4 |
D |
$20.14 |
$1,260,301 |
D/D |
(62,577) |
27,236 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Therap & Clin Prog Dev |
• – – |
2006-10-31 |
4 |
OE |
$9.50 |
$623,150 |
D/D |
60,000 |
19,647 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2011-04-04 |
4 |
D |
$45.53 |
$2,649,527 |
D/D |
(58,193) |
84,465 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-11-05 |
4 |
D |
$567.63 |
$32,865,209 |
D/D |
(57,899) |
64,130 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res & Dev Sciences |
• – – |
2012-06-18 |
4 |
D |
$115.29 |
$6,475,609 |
D/D |
(56,168) |
98,032 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2013-05-10 |
4 |
OE |
$21.92 |
$1,215,201 |
D/D |
55,438 |
104,426 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-02-12 |
4 |
OE |
$16.80 |
$1,094,406 |
D/D |
54,548 |
50,807 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-11-20 |
4 |
OE |
$16.80 |
$915,600 |
D/D |
54,500 |
104,219 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-05-14 |
4 |
OE |
$52.03 |
$7,815,575 |
D/D |
52,500 |
49,005 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-12-03 |
4 |
D |
$632.45 |
$31,845,122 |
D/D |
(50,352) |
50,957 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2010-12-14 |
4/A |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,350 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-02-14 |
4 |
OE |
$16.80 |
$840,000 |
D/D |
50,000 |
140,323 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-08-21 |
4 |
OE |
$399.66 |
$19,983,000 |
D/D |
50,000 |
103,100 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2011-09-06 |
4 |
D |
$65.76 |
$3,226,054 |
D/D |
(49,058) |
84,110 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Therap & Clin Prog Dev |
• – – |
2006-10-31 |
4 |
AS |
$20.00 |
$834,639 |
D/D |
(41,689) |
9,647 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
officerTitle |
• – – |
2006-02-03 |
4 |
OE |
$7.41 |
$296,400 |
D/D |
40,000 |
27,127 |
|
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
